Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

IGFBP-2 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:IGFBP-2, Insulin-Like Growth Factor Binding Protein-2
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RMEE05R 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Urine, Cerebrospinal fluid, Amniotic fluid, Milk, Saliva

Sample Requirements

15 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

2–80 ng/ml

Limit of Detection

0.2 ng/ml

Summary

Features

  • Measures total IGFBP-2 concentration in serum, plasma and in other human body fluids
  • single standards with 2; 10; 20; 40 and 80 ng/ml are
  • Total Incubation time only 1.75 hours
  • 2 Control Sera are provided for quality control purposes according GLP
  • ready-to-use Antibody Conjugate
  • no sample extraction needed
  • Microtiterplate seperately break apart

Research topic

Growth hormone and factor-related products, Oncology

Summary

Insulin-like growth factors (IGFs) regulate the proliferation, differentation, apoptose, cell adhesion and metabolism in various tissues and cell types. The IGF-1, which is produced mainly in liver under the influence of growth hormone (GH), regulates as hormone the linear growth of the bones and the process of sexual maturity, while IGF-2 is mainly a growth factor of fetal tissue. The biological actions of IGF over the IGF-Type-1 receptor are modulated variably through the IGF binding proteins (IGFBP-1 to-6). IGFBP-2 is, after IGFBP-3, the second most frequent IGFBP in the human blood. IGFs, especially tumor typical pro-IGF-forms and hormones regulate the expression of IGFBP-2, GH effect is thereby inhibiting. At cellular level IGFBP-2 seems to stimulate the proliferation and dissemination of solid tumors via an IGF-independent mechanism.

IGFBP-2 is a unglycosylated polypetide of 31.3 kDa, which forms binary IGF-complexes and shows no circadian rhythm in the circulation.The serum concentration of IGFBP-2 increases in fasting, after major surgery and after trauma, but the increasing of the concentration is most intensive in malignant diseases. The correlation of the IGFBP-2 level to the degree of progression is a striking feature in various tumor types as is the normalization of the IGFBP-serum levels after remission. The IGFBP-2 concentration is age-dependent in blood.

Related Products Documents